Phase 4
Completed N=20
Use of Apremilast in Patients Who Are Dissatisfied With Stable Maintenance Topical Therapy
Source: ClinicalTrials.gov NCT03000309 ↗Enrolled (actual)
20
Serious AEs
0.0%
Results posted
Mar 2019
Primary outcomePrimary: Mean Change in Product of BSA (Body Surface Affected by Psoriasis) and sPGA (Static Physician Global Assessment) From Baseline to Week 16 — -9 score on a scale
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
Sixteen week open label study of apremilast in combination with topical steroids with a four week safety follow up visit.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Mean Change in Product of BSA (Body Surface Affected by Psoriasis) and sPGA (Static Physician Global Assessment) From Baseline to Week 16 |
-9 | — |
| PRIMARY Percent Change in Product of BSA and sPGA |
-29 | — |
| SECONDARY Percent Change in Product of BSA and sPGA |
-29 | — |
| SECONDARY Mean Change in DLQI |
-7 | — |
| SECONDARY Mean Change in Pruritus Scores |
-3 | — |
| SECONDARY Mean Change in BSA |
-2 | — |
| SECONDARY Percent Change in BSA |
-36 | — |
| SECONDARY Proportion of Patients Who Achieve PASI 50 |
8 | — |
| SECONDARY Proportion of Patients Who Achieve PASI 75 |
6 | — |
| SECONDARY % of Patients Achieving Clear or Almost Clear on the PtGA |
9 | — |
Eligibility Criteria
Inclusion Criteria
- Subjects must be in general good health as judged by investigator
- Female of childbearing potential (FCBP) must have a negative pregnancy test at screening and Baseline.
- FCBP must use an approved method of contraception as outlined in the protocol.
- Male subjects who engage in activity in which conception is possible must use barrier contraception as defined in the protocol.
- 18 years of age or older
- Understand and voluntarily sign the Informed Consent
- Able to adhere to study visit schedule
- Moderate plaque type psoriasis as define by a a PGA of 3
- BSA 0f 5-10% or a DLQI score of 7 or more
- History of uncontrolled plaque psoriasis after either stable dose of high potency topical steroids for 2 weeks or mid-potency steroids for 4 weeks within the last 6 months
Exclusion Criteria
- Any clinically significant disease as determined by the investigator or major disease that is currently uncontrolled
- Any condition, including the presence of laboratory abnormalities, which would place the subject at unacceptable risk
- Prior history of suicide attempt at any time in the subject's lifetime prior to screening or randomization, or major psychiatric illness requiring hospitalization within the last 3 years
- Pregnant or breastfeeding, FCBP who are not willing to use acceptable birth control methods.
- Active substance abuse or a history of substance abuse within 6 months prior to screening.
- Malignancy or history of malignancy except fo treated (cured) basal cell or or squamous cell in situ skin carcinomas, treated (cured) cervical intraepithelial neoplasia or carcinoma in situ of the cervix with no evidence of recurrence within the previous 5 years
- Has not completed the prescribed washout for restricted treatments
- Known or suspected allergy to investigational product
- Other types of psoriasis
- Prior history of depression
- Prior use of apremilast
Data sourced from ClinicalTrials.gov (NCT03000309). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.